Jason B Fleming

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. ncbi Superficial femoral vein as a conduit for portal vein reconstruction during pancreaticoduodenectomy
    Jason B Fleming
    Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Arch Surg 140:698-701. 2005
  2. ncbi Inactivation of tumor suppressor genes by promoter methylation is important in the pathogenesis of pancreatic cancer
    Jason B Fleming
    Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390-8593, USA
    Cancer Biol Ther 1:297-9. 2002
  3. ncbi Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer
    Jason B Fleming
    The Hamon Center for Therapeutic Oncology Research and the Department of Surgery, University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    J Cell Biochem 90:492-501. 2003
  4. ncbi Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice
    Carlton C Barnett
    Department of Surgery, University of Colorado at Denver, Denver Health Medical Center, Denver, Colorado 80204 0206, USA
    Cancer 116:3862-74. 2010
  5. ncbi Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Cancer Res 68:4340-6. 2008
  6. ncbi Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts
    Shane E Holloway
    Department of Surgery, Division of Surgical Oncology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390-8593, USA
    Ann Surg Oncol 13:1145-55. 2006
  7. ncbi Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature
    Grzegorz Korpanty
    Hamon Center for Therapeutic Oncology Research and Department of Surgery, University of Texas Southwestern Medical Center, Dallas 75390 8593, USA
    Clin Cancer Res 13:323-30. 2007
  8. ncbi Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy
    Jason B Fleming
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593, USA
    Mol Cancer Res 3:413-23. 2005
  9. ncbi Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer
    Shane E Holloway
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
    J Am Coll Surg 200:371-7. 2005
  10. ncbi Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice
    Adam W Beck
    Simmons Comprehensive Cancer Center and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
    Int J Cancer 118:2639-43. 2006

Collaborators

Detail Information

Publications22

  1. ncbi Superficial femoral vein as a conduit for portal vein reconstruction during pancreaticoduodenectomy
    Jason B Fleming
    Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Arch Surg 140:698-701. 2005
  2. ncbi Inactivation of tumor suppressor genes by promoter methylation is important in the pathogenesis of pancreatic cancer
    Jason B Fleming
    Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390-8593, USA
    Cancer Biol Ther 1:297-9. 2002
  3. ncbi Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer
    Jason B Fleming
    The Hamon Center for Therapeutic Oncology Research and the Department of Surgery, University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    J Cell Biochem 90:492-501. 2003
    ..In this review, we will use the example of orthotopic mouse models of pancreatic cancer as a tool to survey the challenges and possibilities of functional imaging of angiogenesis, a critical determinant of metastasis...
  4. ncbi Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice
    Carlton C Barnett
    Department of Surgery, University of Colorado at Denver, Denver Health Medical Center, Denver, Colorado 80204 0206, USA
    Cancer 116:3862-74. 2010
    ....
  5. ncbi Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Cancer Res 68:4340-6. 2008
    ..Our results show an underappreciated mechanism of action that may directly contribute to the antitumor activity of angiogenesis inhibitors that block the VEGFR2 pathway...
  6. ncbi Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts
    Shane E Holloway
    Department of Surgery, Division of Surgical Oncology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390-8593, USA
    Ann Surg Oncol 13:1145-55. 2006
    ..CONCLUSIONS: Blockade of VEGF receptor 2 activation by tumor-derived VEGF decreases tumor vessel function and growth of some human pancreatic adenocarcinoma cell lines in mice...
  7. ncbi Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature
    Grzegorz Korpanty
    Hamon Center for Therapeutic Oncology Research and Department of Surgery, University of Texas Southwestern Medical Center, Dallas 75390 8593, USA
    Clin Cancer Res 13:323-30. 2007
    ..We investigated the use of targeted microbubbles to follow vascular response of therapy in a mouse model of pancreatic adenocarcinoma...
  8. ncbi Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy
    Jason B Fleming
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593, USA
    Mol Cancer Res 3:413-23. 2005
    ..We have found that silencing mutant K-ras through RNAi results in alteration of tumor cell behavior in vitro and suggests that targeting mutant K-ras specifically might be effective against pancreatic cancer in vivo...
  9. ncbi Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer
    Shane E Holloway
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
    J Am Coll Surg 200:371-7. 2005
    ..Protein analysis confirms the microarray results and collocalization of Cyr61, and alpha(v) suggests that interaction between Cyr61 and alpha(v)beta(3) promotes formation of peritoneal metastases...
  10. ncbi Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice
    Adam W Beck
    Simmons Comprehensive Cancer Center and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
    Int J Cancer 118:2639-43. 2006
    ..In conclusion, 3G4 enhanced the anti-tumor and anti-metastatic activity of gemcitabine without contributing to toxicity...
  11. ncbi Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement
    Daniel E Abbott
    Department of Surgery, University of Cincinnati, Cincinnati, OH, USA
    Ann Surg Oncol 19:3659-67. 2012
    ..Our objective was to compare the cost-effectiveness of various treatment strategies for resectable pancreatic head adenocarcinoma, and to identify opportunities for improved cost effectiveness...
  12. ncbi Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation
    Matthew H G Katz
    Department of Surgery, The University of California, Orange, CA, USA
    Ann Surg Oncol 17:1794-801. 2010
    ..We evaluated CA 19-9 as a marker of therapeutic response, completion of therapy, and survival in patients enrolled on two recently reported clinical trials...
  13. ncbi Surgical therapy of peptic ulcers in the 21st century: more common than you think
    George A Sarosi
    Department of Surgery, North Texas Veterans Administration Medical Center, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Am J Surg 190:775-9. 2005
    ..The purpose of this study was to characterize the Veteran patients undergoing surgery for peptic ulcer disease in a modern series and to examine the effect of H. pylori status on surgical outcome and recurrence of PUD...
  14. ncbi Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
    ..There is no optimal treatment schema for this distinct stage of disease, so the role of surgery is undefined...
  15. ncbi LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
    Davide Melisi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 7:829-40. 2008
    ..Targeting TbetaRI/II kinase activity on pancreatic cancer cells or the cells of the liver microenvironment represents a novel therapeutic approach to prevent pancreatic cancer metastasis...
  16. ncbi Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer
    Rosa F Hwang
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 15:1356-66. 2008
    ..We describe the development of an integrated pancreatic tissue bank (PTB) and clinical database for patients with pancreatic cancer and other pancreatic disorders...
  17. ncbi Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells
    Bailu Peng
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3628-38. 2002
    ..We seek to determine the role of Smad4/DPC4 in the suppression of tumor cell growth and in the regulation of TGF-beta-mediated expression of cell-cycle regulatory genes p15(ink4b) and p21(waf1)...
  18. ncbi Current diagnosis and management of unusual pancreatic tumors
    Melinda M Mortenson
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg 196:100-13. 2008
    ....
  19. ncbi Tumor-node-metastasis staging of pancreatic adenocarcinoma
    Matthew H G Katz
    Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:111-25. 2008
    ....
  20. ncbi Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 207:106-20. 2008
  21. ncbi Focal adhesions and associated proteins in medullary thyroid carcinoma cells
    Lawrence T Kim
    Surgical Service, Central Arkansas Veterans Healthcare System and University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    J Surg Res 111:177-84. 2003
    ..Deranged adhesion-dependent signaling may contribute to MTC pathogenesis...
  22. ncbi Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas
    Dan G Blazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    JOP 9:56-60. 2008
    ..Herein, we report what to our knowledge is the first description of pancreatic resection of metastatic endometrial carcinoma...